Latest Physician Fee Schedule Proposal Could Impact Companies’ Bottom Line
Executive Summary
The US Centers for Medicare & Medicaid Services (CMS) issued a proposed rule that includes new reimbursement levels for multiple medical devices, including the Glaukos iStent.
You may also be interested in...
Updated: iRhythm Continues To Grow Despite Reimbursement, Hospital-Staffing Challenges
Despite intense lobbying from industry and physician groups, CMS chose not to install national pricing for long-term remote cardiac monitoring in its final 2022 Medicare Physician Fee Schedule Final Rule.
CMS Advisory Panel Provides Some Potential Good News For Glaukos
Rate adjustment recommendations to US Medicare could result in less drastic reimbursement cuts for Glaukos than those currently on the table.
Glaukos Takes Another Hit From CMS; Investors Respond Negatively As Stock Falls
The US Medicare agency's new rule for facility fees brings more bad news for Glaukos; Wells Fargo downgrades company’s stock in response.